Extended-spectrum -lactamase production and antimicrobial resistance in Klebsiella pneumoniae and Escherichia coli among inpatients and outpatients of Jimma University Specialized Hospital, South-West, Ethiopia
Authors:
- Moga Siraj ShewkiMSMoga Siraj Shewki
- Ali SolomonASAli Solomon
- Wondafrash BeyeneWBWondafrash Beyene
Open Access
- 22 October 2014
- journal article
- Published by Academic Journals in African Journal of Microbiology Research
- Vol. 8 (43) , 3687-3694
Abstract
Extended spectrum β-lactamases (ESBLs) have emerged as a major threat worldwide with limited treatment options. The prevalence of ESBL producing Escherichia coli and Klebsiella pneumoniae strains largely remain unknown in Ethiopia. The study was aimed at determining the occurrence of extended spectrum β-lactamase-producing E. coli and K. pneumoniae among inpatient and outpatient settings, their antimicrobial resistance profile and associated risk factors in Jimma University Specialized Hospital (JUSH). A total of 471 consecutive, non repetitive clinical specimens were collected among inpatients (n=314) and outpatients (n=157). Among these, 112 isolates of K. pneumoniae (n=27) and E. coli (n=85) were recovered. Overall prevalence of extended spectrum beta lactamase (ESBL) producers was 38.4% (n=43) of total isolates. Extended spectrum beta lactamases were found in 28.2% (n=24) of E. coli and 70.4% (n=19) of K. pneumoniae. Extended spectrum beta lactamase producers mediated very high resistance to both beta-lactams and non-betalactams, and they were significantly higher among in-patients (46.4%) than out-patients (14.3%). On Multivariate analysis, treatment with third generation cephalosporin was identified as a sole risk factor for acquisition of ESBL enzyme. Our findings confirmed that infection due to extended spectrum beta lactamase-producing E. coli and K. pneumonia is prevalent in JUSH and that exposure to third generation cephalosporin was associated with these infections. The magnitude of E. coli and K. pneumoniae infection was more in inpatients with higher levels of extended spectrum beta lactamase production than outpatients. Key words: Escherichia coli, Klebsiella pneumoniae, extended spectrum β-lactamases, inpatients, outpatients.Keywords
This publication has 19 references indexed in Scilit:
- Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009)Clinical Microbiology and Infection, 2012
- Extended-spectrum β-lactamase-producing Escherichia coli strains in the feces of carriers contribute substantially to urinary tract infections in these patientsInfection, 2011
- Colonisation by extended-spectrum β-lactamase-producing Klebsiella spp. in a paediatric intensive care unitJournal of Hospital Infection, 2010
- Antimicrobial resistance in Europe and its potential impact on empirical therapyClinical Microbiology and Infection, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Extended Spectrum β-Lactamases among Gram-negative bacteria from an Egyptian pediatric hospital: a two-year experienceThe Journal of Infection in Developing Countries, 2007
- Multidrug resistance in Gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs)Clinical Microbiology and Infection, 2005
- Extended-Spectrum β-Lactamase–ProducingEscherichia coliandKlebsiellaSpecies: Risk Factors for Colonization and Impact of Antimicrobial Formulary Interventions on Colonization PrevalenceInfection Control & Hospital Epidemiology, 2002
- Beta-lactamase-mediated resistance and opportunities for its controlJournal of Antimicrobial Chemotherapy, 1998
- Properties of plasmids responsible for production of extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1991